Latest Genentech Stories
BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly...
NEW YORK, LONDON and BERMUDA, Oct. 21 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept® with Avastin®. The patent is based on in vivo data demonstrating the successful inhibition of tumor growth using a combination therapy approach. This patent was filed in April 2010, recognized as "special"...
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.Dr David Spigel, Director of lung cancer research for the Sarah Cannon Research Institute in Nashville, Tennessee reported the trial findings at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.The study...
(Ivanhoe Newswire) "“ Age-related macular degeneration (AMD) is the leading cause of blindness for people over fifty. There are two treatments for AMD, although there is no cure, these treatments reduce the impact that macular degeneration has on vision. The two drugs include Bevacizumab (Avastin) and Ranibizumab (Lucentis). Scientists, for the first time, have discovered that there may not be any difference in the efficacy of these drugs- one is not better than the other.AMD affects...
Science's annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the driving characteristics of the best employers and to determine the 20 best employers in these industries. Respondents to the web-based survey were asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change, and a research-driven environment.This year, Genentech, of San Francisco, California,...
BURLINGTON, Mass., Oct. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010 findings from the topic entitled Non-Small-Cell Lung Cancer reveal that market growth will...
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to...
MENLO PARK, Calif., Sept. 30 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer. (Logo: http://photos.prnewswire.com/prnh/20100513/LA04336LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100513/LA04336LOGO) "We are very pleased to have Merdad as the new CEO of 3-V," said David M. Mott, 3-V's Executive Chairman, who is returning to his role as Chairman of the Board. "Merdad's extensive drug development...
MELBOURNE, Australia, Sept. 29 /PRNewswire/ -- Circadian Technologies (ASX:CIR) has announced today that it has partnered with Cincinnati Children's Hospital Medical Centre (CCHMC) to develop and market a blood test to diagnose LAM, a serious lung disease that strikes women, usually in their child bearing years. The diagnostic is being developed following the discovery that high levels of vascular endothelial growth factor-D, or VEGF-D - to which Circadian owns intellectual property rights...
NOVATO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. "We are extremely pleased to welcome William Young and Kenneth Bate to our Board of Directors. With experience, vision and proven strength in leadership and execution, they are both exceptionally qualified to take on this important role in the company," said Pierre Lapalme, Chairman of the Board of...
